Experts outline treatment options for patients with venetoclax resistance.
Researchers sought to determine the cost-effectiveness of CAR-T therapy compared with standard of care in patients with DLBCL.
Researchers sought to determine whether using high-dose methotrexate would lead to increased risks in patients with lymphoma.
Researchers sought to determine whether adding atezolizumab to an obinutuzumab-bendamustine chemoimmunotherapy regimen would improve survival in FL.
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
The approval was based on data from the open-label phase 3 AHOD1331 trial.
Researchers developed an instrument to identify unmet needs and quality-of-life outcomes for patients with lymphoma.
Researchers sought to determine whether allo-HSCT would be effective for inducing durable remission among patients with relapsed or refractory PMBCL.
Researchers sought to determine whether UCBT with FM-based reduced-intensity conditioning would improve survival outcomes in patients with lymphoma.
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
Researchers sought to identify links between the expression of 2 proteins and prognosis in patients with diffuse large B-cell lymphoma.
Researchers sought to identify novel therapeutic approaches to patients who develop Richter transformation.
Researchers sought to determine whether first-line rituximab plus bendamustine followed by ASCT would be an effective treatment option for MCL.
Researchers sought to determine whether MRD may predict relapse risk in patients with MCL.
Researchers sought to determine the vaccination-induced immune responses among patients with hematologic malignancies.
Researchers sought to determine risk predictors for coronary heart disease and heart failure in Hodgkin lymphoma survivors who were aged 18 to 50 at diagnosis.
Researchers sought to determine whether CAR-T therapy following pembrolizumab treatment would be effective in patients with relapsed/refractory DLBCL.
Researchers sought to validate a new prognostic tool for patients with aggressive large B-cell lymphoma.
The incidence of cutaneous T-cell lymphoma in the United States increased from 2000 to 2018, with an annual percent change of 0.61%.
Researchers sought to determine whether PLM60 with pegaspargase would have efficacy in patients with extranodal natural killer/T-cell lymphoma.
The aim of this trial was to evaluate the efficacy and safety of orelabrutinib with RCHOP in patients with extranodal non-GCB DLBCL.
Long-acting G-CSF can reduce the risk of hospitalization related to febrile neutropenia in patients with DLBCL treated with R-CHOP.
Researchers sought to identify genomic features in patients with large B-cell lymphoma that are linked with anti-CD19 CAR-T therapy.
Researchers sought to determine the clinical, therapy, and outcome patterns of patients with WM in Latin America.
Researchers sought to determine patterns in coagulation parameters linked to cytokine-release syndrome in patients receiving CAR-T therapy.
Researchers sought to determine whether adding brentuximab vedotin to AVD would improve survival in patients with stage III or IV Hodgkin lymphoma.
Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
Rates and patterns of development of severe cytopenias in patients after axicabtagene ciloleucel therapy for large B-cell lymphoma were identified.
TPO receptor agonist treatment for severe persistent cytopenia associated with CAR-T therapy resulted in complete cytopenia remission among most patients.
Researchers sought to develop a gene expression-based subclassification for improved PTCL diagnosis.
Researchers sought to determine whether brentuximab vedotin plus AVD would improve responses in patients with previously untreated, early-stage unfavorable HL.
The researchers sought to evaluate the long-term outcomes and toxicities of the treatments in the PRECIS study.
Researchers investigated a hypothesis that posttreatment bone marrow biopsy may not be needed after confirming complete response on imaging in patients with follicular lymphoma.
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules.
Vaccine effectiveness against breakthrough SARS-CoV-2 infections was 10.5% for patients with lymphoma.
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Mosunetuzumab produced an objective response rate of 80%.
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Researchers sought to determine the trends in the utilization of Medicare on short-course radiotherapy in patients with lymphoma.
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Researchers sought to determine whether the combination pola-R-CHP would be cost-effective for treating patients with previously untreated DLBCL.
Researchers sought to determine the role and utilization of ASCT in younger patients with MCL.
Romidepsin is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma.
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.